Trials / Completed
CompletedNCT03649750
Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
A Phase I, Open-label, Single-dose, Randomized, 2-way Cross-over Study Designed to Examine the Relative Bioavailability of Guaifenesin When a Mucinex Extended Release 600 mg Bi-layer Tablet is Taken Under Fasted Compared to Fed Conditions in Normal Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Reckitt Benckiser LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Determine and compare the plasma concentrations of Mucinex® Extended Release (ER) 600 mg bi-layer tablet in normal healthy volunteers in fed and fasting conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mucinex® | Mucinex® 600 mg ER bi-layer tablets |
Timeline
- Start date
- 2013-05-29
- Primary completion
- 2013-08-07
- Completion
- 2013-08-07
- First posted
- 2018-08-28
- Last updated
- 2019-03-27
- Results posted
- 2019-02-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03649750. Inclusion in this directory is not an endorsement.